Cannabis Pioneer Joe Caltabiano Donates $250,000 to Gateway for Cancer ResearchSM to Improve Pediatric Cancer Treatment Options


Ryan Allway

August 16th, 2022

News, Top News


Gift was inspired by Caltabiano’s experience as a survivor of childhood leukemia

CHICAGO (August 16, 2022) —  With a goal to help researchers find a new treatment approach for children fighting cancer recurrence, cannabis industry pioneer Joe Caltabiano has made a transformative gift of $250,000 to Gateway for Cancer ResearchSM (Gateway), a nonprofit organization dedicated to funding transformational early-phase cancer research.

A survivor of childhood cancer, Caltabiano was diagnosed with Acute Lymphoblastic Leukemia, a cancer of the blood and bone marrow, when he was just seven years old. He has cited the diagnosis as being one of the most profound moments of his life, as well as a motivating factor for his work in the cannabis industry. A Gateway Board member since 2016, Caltabiano has made finding a cure for cancer one of his life’s goals.

“Gateway Concierge allows visionary benefactors like Joe to channel their personal passion for fighting cancer into purpose by co-creating new possibilities in cancer care with world-class clinician-scientists. This funding will dramatically improve the lives of children undergoing treatment for leukemia,” said Jessica Cestone, Executive Director, Gateway Concierge. “For a project of this scale, collaboration is key to its success. The timing of Joe’s transformative gift allowed Gateway to sign on as one of the early funders of the trial to help accelerate the discovery of new and effective treatments that will provide lasting cures for children with blood cancer.”

Gateway utilized Caltabiano’s gift to provide a grant to The Leukemia & Lymphoma Society (LLS) to support the Pediatric Acute Leukemia (PedAL) Master Clinical, an international collaboration to expedite the development of new targeted treatments for childhood leukemias. All patients enrolling on the PedAL trial will receive genetic sequencing and biomarker screening to identify the individual molecular drivers of their disease. Each patient will then be matched to a sub-trial of targeted therapy that is the best match for their unique genetic information.

“Despite the challenges of my treatment and recovery, I actually view my childhood leukemia journey as one of the best things that ever happened to me because it gave me a unique perspective that helps guide my attitude to this day. It is hard to have a bad day once you have survived cancer,” Caltabiano said. “I want more kids going through cancer treatment to have the opportunity to feel this same way. Recovering from leukemia is really tough, especially when you are a child. The Gateway Concierge program provides such an incredible opportunity to make a real difference.”

Founded in 1991, Gateway is one of the only nonprofits solely dedicated to funding Phase I and II clinical trials for cancers of all types, urgently bringing breakthroughs to the bedside for courageous patients and their families. As a survivor of childhood cancer, Caltabiano understands all too well the urgent need to change the course of treatment for children with relapsed leukemia.

“For children with relapsed acute leukemia, there is no standard of care, and their prognosis is poor. As a childhood cancer survivor, I chose to invest in Gateway because of its targeted mission to fund early phase research, which is where cancer breakthroughs happen,” Caltabiano said. “It is an honor and privilege to be associated with Gateway and its important work.”

Caltabiano is a respected voice in today’s emergent cannabis industry and regularly provides guidance to startups and established companies alike. Caltabiano is founder of JSC Fund where he seeks to uncover and advance opportunities within the cannabis market. Prior to launching JSC Fund, Caltabiano co-founded Cresco Labs, one of North America’s largest vertically integrated cannabis operators. During his tenure, Caltabiano grew Cresco Labs from a startup to a Multi-state Operator with annualized revenue of over $250 million and operations spanning nine states.

For more information about the Gateway Concierge program, please visit GatewayCR.org. To schedule an interview, contact Shawna Seldon McGregor at [email protected] or 917-971-7852.

###

Shawna Seldon McGregor

Maverick Public Relations
917-971-7852

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading